-
Biosimilars bring price pressure, but are they sufficiently used?
When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.
-
EMA: Inflammation i hjärtat möjlig biverkning av nya covidvaccinet
Den europeiska läkemedelsmyndigheten EMA har kommit fram till att covidvaccinet Nuvaxovid i sällsynta fall kan ge biverkningar i form av myokardit och perikardit, det vill säga hjärtmuskelinflammation och inflammation i hjärtsäcken.
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.